Evaluating the diagnostic accuracy of transperineal prostate biopsy in unilateral MRI-target lesions
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background To evaluate the diagnostic value of target biopsies (TargB), TargB with ipsilateral systematic (TargB+IS), and TargB with contralateral systematic biopsies (TargB+CS) for the detection of clinically significant prostate cancer (csPCa).Methods A prospective evaluation of patients undergoing MRI-Ultrasound fusion transperineal biopsy was performed between January 2023 and February 2025. Patients with unilateral MRI-visible lesions (PIRADS grade 3–5) and PSA between 4 and 20 ng/mL were enrolled. The diagnostic accuracy of TargB (group 1), TargB+IS (group 2), and TargB+CS (group 3) was evaluated versus the presence of csPCa in any systematic or target biopsy (reference standard).Results 384 patients were included (PIRADS III in 180 (46.9%), IV in 152 (39.6%), and V in 52 (13.5%) patients). The sensitivity and NPV of TargB was 87.5%, and 93%, TargB+CS were 91.7% and 95.2%, and TargB+IS were 97.2% and 98.4%, respectively. TargB+IS achieved the highest negative predictive value (98.4%) across all PIRADS groups and when stratified according to the PIRADS score. The agreement between TargB+IS and csPCa was almost perfect (Kappa: 0.98, p < 0.001), with non-significant discordance (McNemar p = 0.1).Conclusions TargB+IS provides the lowest false-negative rate for csPCa detection compared to TargB alone or TargB+CS. Contralateral systematic biopsies may be omitted in selected patients, but ipsilateral systematic sampling remains essential to minimize missed diagnoses.
Fields of Study & Subjects
Prostate Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Radiomics and Machine Learning in Medical Imaging
Publication details
- Journal / source
- Arab Journal of Urology
- Pages
- 1–6
- Publication date
- 27 March 2026
- Language
- EN